155 related articles for article (PubMed ID: 20851082)
1. HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization.
D'Antuono A; Laimbacher AS; La Torre J; Tribulatti V; Romanutti C; Zamorano P; Quattrocchi V; Schraner EM; Ackermann M; Fraefel C; Mattion N
Vaccine; 2010 Oct; 28(46):7363-72. PubMed ID: 20851082
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses.
Borrego B; Fernandez-Pacheco P; Ganges L; Domenech N; Fernandez-Borges N; Sobrino F; Rodríguez F
Vaccine; 2006 May; 24(18):3889-99. PubMed ID: 16563575
[TBL] [Abstract][Full Text] [Related]
3. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice.
Yang B; Lan X; Li X; Yin X; Li B; Han X; Li Y; Zhang Z; Liu J
Vaccine; 2008 Oct; 26(43):5477-83. PubMed ID: 18694793
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccination against foot-and-mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity.
Kim SA; Liang CM; Cheng IC; Cheng YC; Chiao MT; Tseng CJ; Lee F; Jong MH; Tao MH; Yang NS; Liang SM
J Gene Med; 2006 Sep; 8(9):1182-91. PubMed ID: 16927362
[TBL] [Abstract][Full Text] [Related]
5. HSV-1 amplicon vectors as genetic vaccines.
Laimbacher AS; Fraefel C
Methods Mol Biol; 2014; 1144():99-115. PubMed ID: 24671679
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
Yao Q; Qian P; Huang Q; Cao Y; Chen H
J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
[TBL] [Abstract][Full Text] [Related]
7. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response.
Moraes MP; Segundo FD; Dias CC; Pena L; Grubman MJ
Vaccine; 2011 Nov; 29(51):9431-40. PubMed ID: 22027486
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus--importance of dominant and subdominant epitopes for antigenicity and protection.
Frimann TH; Barfoed AM; Aasted B; Kamstrup S
Vaccine; 2007 Aug; 25(33):6191-200. PubMed ID: 17640782
[TBL] [Abstract][Full Text] [Related]
9. [Molecular design and immunogenicity of a multiple-epitope foot-and-mouth disease virus antigen, adjuvants, and DNA vaccination].
Ma M; Jin N; Yin G; Lu H; Li C; Jin K; Qu Z
Sheng Wu Gong Cheng Xue Bao; 2009 Apr; 25(4):514-9. PubMed ID: 19637624
[TBL] [Abstract][Full Text] [Related]
10. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice.
Ren ZJ; Tian CJ; Zhu QS; Zhao MY; Xin AG; Nie WX; Ling SR; Zhu MW; Wu JY; Lan HY; Cao YC; Bi YZ
Vaccine; 2008 Mar; 26(11):1471-81. PubMed ID: 18289743
[TBL] [Abstract][Full Text] [Related]
11. DNA immunization with 2C FMDV non-structural protein reveals the presence of an immunodominant CD8+, CTL epitope for Balb/c mice.
Barfoed AM; Rodriguez F; Therrien D; Borrego B; Sobrino F; Kamstrup S
Antiviral Res; 2006 Dec; 72(3):178-89. PubMed ID: 16890298
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18.
Mingxiao M; Ningyi J; Juan LH; Min Z; Guoshun S; Guangze Z; Huijun L; Xiaowei H; Minglan J; Xu L; Haili M; Yue J; Gefen Y; Kuoshi J
Antiviral Res; 2007 Oct; 76(1):59-67. PubMed ID: 17606304
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus.
Li X; Liu R; Tang H; Jin M; Chen H; Qian P
Vaccine; 2008 May; 26(22):2714-22. PubMed ID: 18436351
[TBL] [Abstract][Full Text] [Related]
14. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
Grubman MJ
Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
16. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine.
Pena L; Moraes MP; Koster M; Burrage T; Pacheco JM; Segundo FD; Grubman MJ
Vaccine; 2008 Oct; 26(45):5689-99. PubMed ID: 18762225
[TBL] [Abstract][Full Text] [Related]
17. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus.
Zheng M; Jin N; Zhang H; Jin M; Lu H; Ma M; Li C; Yin G; Wang R; Liu Q
J Virol Methods; 2006 Sep; 136(1-2):230-7. PubMed ID: 16780963
[TBL] [Abstract][Full Text] [Related]
18. Early detection and visualization of human adenovirus serotype 5-viral vectors carrying foot-and-mouth disease virus or luciferase transgenes in cell lines and bovine tissues.
Montiel N; Smoliga G; Arzt J
Vaccine; 2012 Feb; 30(9):1690-701. PubMed ID: 22227230
[TBL] [Abstract][Full Text] [Related]
19. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs.
Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D.
García-Briones MM; Blanco E; Chiva C; Andreu D; Ley V; Sobrino F
Virology; 2004 May; 322(2):264-75. PubMed ID: 15110524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
